The linked FDA records tie DePuy, Inc. to a single PMA number, P830055, under product code NJL and the Orthopedic advisory committee. All ten linked records are PMA entries, and the collection shows nine OK30 decisions and one APPR decision as of the snapshot date. The five most recent records in the sample are all 30-Day Notice supplements decided in October 2026, each describing a manufacturing or inspection process change rather than a new clinical indication. [1][2][3]

Documented knee systems under P830055

The filings describe the regulated device as a prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing, classified as device class 3. Trade names appearing across the records include the LCS Knee System, the LCS Total Knee System, the ATTUNE Rotating Platform Total Knee System, the ATTUNE Revision Rotating Platform Knee System, and the ATTUNE Revision Knee System. The ATTUNE Revision Rotating Platform (RP) Tibial Base product family is named within the scope of one supplement. [1][2][3][4][5]

October 2026 supplement activity

Supplement S378 for the LCS Knee System, received 28 September 2026 and decided 27 October 2026, covers introduction of an in-house X-ray inspection process at the DePuy Synthes manufacturing facility in Raynham, Massachusetts. Supplement S381, received 1 October 2026 and decided the same day as S378, covers addition of a new Coherent Laser Automatic Processing System at the same Raynham facility for the ATTUNE Rotating Platform and ATTUNE Revision Rotating Platform systems. [1][2]

Supplement S379 for the ATTUNE Revision Knee System, received 29 September 2026 and decided 9 October 2026, covers removal of the routine 100 percent inspection requirement for Critical to Quality characteristics of the laser marking systems during manufacturing of the ATTUNE Revision Rotating Platform Tibial Base product family. Supplement S380 for the LCS Total Knee System, received 30 September 2026 and decided 5 October 2026, covers removal of a duplicate inspection performed at the DePuy Cork facility for the Attune CR Femoral Components. [3][5]

Supplement S377, received 14 September 2026 and decided 8 October 2026, covers an additional hot isostatic pressure parameter cycle at supplier Lake City Heat Treating for some metallic components approved under the LCS Total Knee System. Its listed trade names also include the ATTUNE Rotating Platform and ATTUNE Revision Rotating Platform systems and a truncated M.B.T. entry. [4]

Applicant identity and filing address

The applicant field on each record reads Depuy, Inc., with a mailing address of P.O. Box 988, 700 Orthopaedic Dr., Warsaw, Indiana. That address appears in FDA filing data and is not treated here as a verified corporate headquarters. The records do not establish a parent company, brand ownership, website, customer base, or commercial availability, and none is asserted. [1][2][3]

How to read the collection counts

The ten linked records and the nine OK30 versus one APPR split describe the supplied filing collection as of 20 November 2026, not total company sales, total portfolio, or safety performance. The five-record sample is smaller than the full collection and shows five OK30 decisions; its counts apply only to that sample and are not a subset ratio for the whole. [1][2][3][4][5]